IL107035A - Method to destroy or impair target cells in animal blood - Google Patents
Method to destroy or impair target cells in animal bloodInfo
- Publication number
- IL107035A IL107035A IL10703593A IL10703593A IL107035A IL 107035 A IL107035 A IL 107035A IL 10703593 A IL10703593 A IL 10703593A IL 10703593 A IL10703593 A IL 10703593A IL 107035 A IL107035 A IL 107035A
- Authority
- IL
- Israel
- Prior art keywords
- target cells
- bpd
- blood
- cells
- light
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 29
- 210000004369 blood Anatomy 0.000 title claims description 62
- 239000008280 blood Substances 0.000 title claims description 62
- 230000005855 radiation Effects 0.000 claims abstract description 26
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 244000045947 parasite Species 0.000 claims abstract description 6
- 244000005700 microbiome Species 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 11
- 150000004032 porphyrins Chemical class 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims description 6
- 229960004293 porfimer sodium Drugs 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 4
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000906 photoactive agent Substances 0.000 claims 13
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical group C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims 8
- 230000001678 irradiating effect Effects 0.000 claims 6
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims 6
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims 4
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims 3
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 claims 3
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims 3
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 abstract description 29
- 208000032839 leukemia Diseases 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 69
- 241000699670 Mus sp. Species 0.000 description 49
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 238000011282 treatment Methods 0.000 description 25
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000001782 photodegradation Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010034972 Photosensitivity reaction Diseases 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002165 photosensitisation Effects 0.000 description 5
- 230000036211 photosensitivity Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010073306 Exposure to radiation Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 3
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 3
- 238000011765 DBA/2 mouse Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 150000004036 bacteriochlorins Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000004035 chlorins Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229950003776 protoporphyrin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002186 photoactivation Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- -1 phthalocyanines Chemical class 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 238000005362 photophoresis Methods 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94811392A | 1992-09-21 | 1992-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL107035A0 IL107035A0 (en) | 1993-12-28 |
| IL107035A true IL107035A (en) | 1998-12-27 |
Family
ID=25487290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10703593A IL107035A (en) | 1992-09-21 | 1993-09-20 | Method to destroy or impair target cells in animal blood |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5484803A (fr) |
| EP (1) | EP0660712B1 (fr) |
| JP (2) | JP3598306B2 (fr) |
| AT (1) | ATE201596T1 (fr) |
| AU (1) | AU681088B2 (fr) |
| CA (1) | CA2144327C (fr) |
| DE (1) | DE69330277T2 (fr) |
| DK (1) | DK0660712T3 (fr) |
| ES (1) | ES2160600T3 (fr) |
| FI (1) | FI951295A (fr) |
| GR (1) | GR3036479T3 (fr) |
| HU (1) | HU220251B (fr) |
| IL (1) | IL107035A (fr) |
| NO (1) | NO951066L (fr) |
| NZ (1) | NZ255302A (fr) |
| PL (1) | PL308116A1 (fr) |
| PT (1) | PT660712E (fr) |
| SK (1) | SK35295A3 (fr) |
| TW (1) | TW241204B (fr) |
| WO (1) | WO1994006424A1 (fr) |
| ZA (1) | ZA936968B (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710066B2 (en) | 1989-07-28 | 2004-03-23 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US20020058008A1 (en) * | 1989-07-28 | 2002-05-16 | Kennedy James C. | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US5587490A (en) * | 1990-04-16 | 1996-12-24 | Credit Managers Association Of California | Method of inactivation of viral and bacterial blood contaminants |
| US5798238A (en) * | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
| US20040110819A1 (en) * | 1991-10-28 | 2004-06-10 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| PT947222E (pt) * | 1992-11-20 | 2006-09-29 | Univ British Columbia | Metodo de activacao de agentes fotossensiveis |
| WO1996039188A1 (fr) * | 1995-06-05 | 1996-12-12 | Queen's University At Kingston | Procede photochimiotherapeutique faisant appel a de l'acide 5-aminolevulinique ainsi qu'a d'autres precurseurs de porphyrines endogenes |
| US6008211A (en) * | 1995-07-27 | 1999-12-28 | Pdt Pharmaceuticals, Inc. | Photoactivatable compounds comprising benzochlorin and furocoumarin |
| ATE235814T1 (de) * | 1995-11-06 | 2003-04-15 | New York Blood Ct Inc | Behandlung von roten blutzellen zur inaktivierung von virien durch verwendung von pathalocyanine und rotlicht |
| US5895786A (en) | 1996-05-08 | 1999-04-20 | New York Blood Center, Inc. | Method for treating viral infections |
| US6159733A (en) * | 1996-06-20 | 2000-12-12 | New York Blood Center, Inc. | Method for photoinactivating malignant cells |
| US5922278A (en) † | 1996-11-19 | 1999-07-13 | Baxter International Inc. | Method and apparatus for inactivating contaminants in biological fluid |
| US5742380A (en) * | 1996-12-31 | 1998-04-21 | Ronn Avigdor M | Plasma assay spectrometer |
| US6010890A (en) * | 1997-04-29 | 2000-01-04 | New York Blood Center, Inc. | Method for viral inactivation and compositions for use in same |
| US6103706A (en) * | 1997-04-29 | 2000-08-15 | New York Blood Center, Inc. | Methods for treating viral infections |
| US5856566A (en) * | 1997-09-02 | 1999-01-05 | Dusa Pharmaceuticals, Inc. | Sterilized 5-aminolevulinic acid |
| US6159178A (en) | 1998-01-23 | 2000-12-12 | Heartport, Inc. | Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested |
| US6096066A (en) * | 1998-09-11 | 2000-08-01 | Light Sciences Limited Partnership | Conformal patch for administering light therapy to subcutaneous tumors |
| US6183773B1 (en) | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| JP2002534218A (ja) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | 非侵襲性の脈管療法 |
| CA2358662A1 (fr) * | 1999-01-15 | 2000-07-20 | James Chen | Compositions et procedes destines au traitement de troubles metaboliques osseux et de metastases osseuses |
| US6454789B1 (en) * | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
| US6376483B1 (en) | 1999-05-27 | 2002-04-23 | Miravant Pharmaceuticals, Inc. | Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production |
| US20030114434A1 (en) * | 1999-08-31 | 2003-06-19 | James Chen | Extended duration light activated cancer therapy |
| DE19960705A1 (de) * | 1999-12-16 | 2001-06-21 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine) |
| US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
| US20020049247A1 (en) * | 2000-01-12 | 2002-04-25 | Chen James C. | Novel treatment for eye disease |
| KR100365151B1 (ko) * | 2000-05-08 | 2003-02-11 | 김형락 | 어류 병원성 세균과 바이러스의 감염 예방 및 치료를 위한δ-아미노레불린산의 신규한 용도 |
| DE10034673C1 (de) | 2000-07-17 | 2002-04-25 | Medac Klinische Spezialpraep | Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung |
| EP2248536A3 (fr) | 2000-12-14 | 2010-12-08 | The General Hospital Corporation doing business as Massachusetts General Hospital | Thérapie photodynamique de l'acné vulgaire par application topique d'acide aminolévulinique |
| WO2002013788A1 (fr) | 2000-08-16 | 2002-02-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Therapie photodynamique topique a l'acide aminolevulinique pour l'acne juvenile |
| US7498029B2 (en) * | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
| DE60219627T2 (de) * | 2001-06-04 | 2008-02-07 | The General Hospital Corp., Boston | Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen |
| DE10162712A1 (de) * | 2001-12-19 | 2003-07-17 | Blutspendienst Der Landesverba | Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten |
| JP2005527493A (ja) * | 2002-01-23 | 2005-09-15 | ライト サイエンシーズ コーポレイション | 光線力学療法のためのシステムおよび方法 |
| AU2003248747A1 (en) | 2002-06-27 | 2004-01-19 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| EP2036908A3 (fr) | 2002-07-02 | 2009-05-13 | Health Research, INC. | Synthèse efficace de dérivés de pyrophéophorbide a |
| US7659301B2 (en) * | 2003-04-15 | 2010-02-09 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
| US7220778B2 (en) * | 2003-04-15 | 2007-05-22 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
| US20070020272A1 (en) * | 2003-04-30 | 2007-01-25 | Tayyaba Hasan | Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof |
| AU2004243004A1 (en) * | 2003-05-29 | 2004-12-09 | Mitos Pharmaceuticals, Inc. | Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers |
| FR2857264A1 (fr) * | 2003-07-09 | 2005-01-14 | Maco Pharma Sa | Procede d'inactivation photodynamique des pathogenes au moyen d'ala |
| GB0424833D0 (en) | 2004-11-10 | 2004-12-15 | Photocure Asa | Method |
| US8585707B2 (en) | 2006-06-07 | 2013-11-19 | Gary S. Rogers | Continuous low irradiance photodynamic therapy method |
| US20080164224A1 (en) * | 2007-01-04 | 2008-07-10 | Whirlpool Corporation | System for connecting mechnically dissimilar consumer electronic devices to an adaptor or a host |
| CA2724949A1 (fr) | 2007-06-27 | 2008-12-31 | The General Hospital Corporation | Procede et appareil d'inhibition optique de traitement photodynamique |
| US20090062724A1 (en) * | 2007-08-31 | 2009-03-05 | Rixen Chen | System and apparatus for sonodynamic therapy |
| US8835104B2 (en) | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
| EP2694131B1 (fr) | 2011-04-07 | 2019-08-28 | Fenwal, Inc. | Procédés et systèmes automatisés pour produire des concentrés de plaquettes avec des volumes de plasma résiduel réduits et des milieux de conservation pour de tels concentrés de plaquettes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US4961920A (en) * | 1988-12-08 | 1990-10-09 | Luminis Pty, Ltd. | Phototherapeutic monovinyl and divinyl ether-linked dimers |
| US4960408A (en) * | 1989-01-10 | 1990-10-02 | Klainer Albert S | Treatment methods and vaccines for stimulating an immunological response against retroviruses |
-
1993
- 1993-09-20 JP JP50762994A patent/JP3598306B2/ja not_active Expired - Fee Related
- 1993-09-20 PL PL93308116A patent/PL308116A1/xx unknown
- 1993-09-20 DE DE69330277T patent/DE69330277T2/de not_active Expired - Fee Related
- 1993-09-20 NZ NZ255302A patent/NZ255302A/en unknown
- 1993-09-20 IL IL10703593A patent/IL107035A/en not_active IP Right Cessation
- 1993-09-20 ES ES93918860T patent/ES2160600T3/es not_active Expired - Lifetime
- 1993-09-20 AT AT93918860T patent/ATE201596T1/de not_active IP Right Cessation
- 1993-09-20 SK SK352-95A patent/SK35295A3/sk unknown
- 1993-09-20 EP EP93918860A patent/EP0660712B1/fr not_active Expired - Lifetime
- 1993-09-20 CA CA002144327A patent/CA2144327C/fr not_active Expired - Fee Related
- 1993-09-20 PT PT93918860T patent/PT660712E/pt unknown
- 1993-09-20 WO PCT/CA1993/000382 patent/WO1994006424A1/fr active IP Right Grant
- 1993-09-20 DK DK93918860T patent/DK0660712T3/da active
- 1993-09-20 HU HU9500814A patent/HU220251B/hu not_active IP Right Cessation
- 1993-09-20 AU AU49405/93A patent/AU681088B2/en not_active Ceased
- 1993-09-21 ZA ZA936968A patent/ZA936968B/xx unknown
- 1993-10-05 TW TW082108212A patent/TW241204B/zh active
-
1995
- 1995-02-02 US US08/384,440 patent/US5484803A/en not_active Expired - Lifetime
- 1995-03-20 FI FI951295A patent/FI951295A/fi unknown
- 1995-03-20 NO NO951066A patent/NO951066L/no not_active Application Discontinuation
- 1995-11-08 US US08/555,235 patent/US5736563A/en not_active Expired - Fee Related
-
2001
- 2001-04-04 JP JP2001105544A patent/JP2001316288A/ja active Pending
- 2001-08-30 GR GR20010401338T patent/GR3036479T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU681088B2 (en) | 1997-08-21 |
| SK35295A3 (en) | 1996-05-08 |
| ATE201596T1 (de) | 2001-06-15 |
| JP2001316288A (ja) | 2001-11-13 |
| FI951295A0 (fi) | 1995-03-20 |
| US5484803A (en) | 1996-01-16 |
| NO951066D0 (no) | 1995-03-20 |
| DE69330277T2 (de) | 2002-04-18 |
| CA2144327A1 (fr) | 1994-03-31 |
| FI951295A (fi) | 1995-05-17 |
| GR3036479T3 (en) | 2001-11-30 |
| ES2160600T3 (es) | 2001-11-16 |
| HUT70966A (en) | 1995-11-28 |
| NZ255302A (en) | 2001-04-27 |
| US5736563A (en) | 1998-04-07 |
| PL308116A1 (en) | 1995-07-24 |
| DE69330277D1 (de) | 2001-07-05 |
| JPH08501301A (ja) | 1996-02-13 |
| PT660712E (pt) | 2001-11-30 |
| AU4940593A (en) | 1994-04-12 |
| HU220251B (hu) | 2001-11-28 |
| ZA936968B (en) | 1994-04-12 |
| EP0660712A1 (fr) | 1995-07-05 |
| NO951066L (no) | 1995-05-19 |
| IL107035A0 (en) | 1993-12-28 |
| CA2144327C (fr) | 2002-08-06 |
| WO1994006424A1 (fr) | 1994-03-31 |
| JP3598306B2 (ja) | 2004-12-08 |
| TW241204B (fr) | 1995-02-21 |
| EP0660712B1 (fr) | 2001-05-30 |
| DK0660712T3 (da) | 2001-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5484803A (en) | Transcutaneous in vivo activation of photosensitive agents in blood | |
| EP0680365B1 (fr) | Activation d'agents photosensibles | |
| KR100433507B1 (ko) | 광역학적요법에의한시력개선용약제학적조성물 | |
| AU2002340659B2 (en) | Photodynamic therapy for the treatment of hair loss | |
| Zhou et al. | An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins | |
| JP3174821B2 (ja) | 血液中の選択的な細胞不活性化用医薬組成物 | |
| JPH10508577A (ja) | 血液中の選択的細胞不活性化および免疫機能不全疾患の処置における光力学治療 | |
| CA2270558C (fr) | Traitement de maladies auto-immunes par photochimiotherapie | |
| Ma et al. | Effects of light exposure on the uptake of photofrin II in tumors and normal tissues | |
| US20020115649A1 (en) | Use of texaphyrins in macrophage-mediated disease | |
| AU4860899A (en) | Use of texaphyrins in macrophage-mediated disease | |
| JPS61240970A (ja) | 悪性腫瘍抑制方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| HC | Change of name of proprietor(s) | ||
| RH1 | Patent not in force |